A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants
PHASE1CompletedINTERVENTIONAL
Enrollment
54
Participants
Timeline
Start Date
November 21, 2023
Primary Completion Date
July 19, 2024
Study Completion Date
July 19, 2024
Conditions
Healthy Volunteers
Interventions
BIOLOGICAL
VIS954
A humanized IgG4 monoclonal antibody.
OTHER
Placebo
VIS954 Placebo
Trial Locations (1)
92801
Visterra Clinical Site, Anaheim
All Listed Sponsors
lead
Visterra, Inc.
INDUSTRY
NCT06212804 - A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter